BSE has notified trading members that 31,75,000 new equity shares of Concord Drugs Limited (Scrip Code: 538965) are listed and permitted to trade on the Exchange effective Tuesday, April 21, 2026. The shares were issued on a preferential basis to Promoter and Non-Promoter entities at an issue price of Rs. 36.30 per share (face value Rs. 10 + premium Rs. 26.30).

Key Points

• 31,75,000 equity shares of Rs. 10/- each issued at a premium of Rs. 26.30/- on a preferential basis
• Issue price: Rs. 36.30/- per share
• ISIN: INE858L01010
• Date of allotment: 20 November 2025
• New shares rank pari-passu with existing equity shares
• Distribution numbers: 10000001 to 13175000
• Trading effective from April 21, 2026

Regulatory Changes

No new regulatory changes. This is a standard listing notice under BSE’s Listing Operations for newly allotted preferential shares.

Compliance Requirements

• Trading members must note the lock-in restrictions before executing trades in the newly listed shares
• Shares under lock-in cannot be sold until the respective lock-in expiry dates

Important Dates

• Date of Allotment: 20 November 2025
• Listing / Trading Commencement: 21 April 2026
• Lock-in Expiry (5,00,000 shares | Dist. Nos. 10000001–10500000): 30 October 2027
• Lock-in Expiry (26,75,000 shares | Dist. Nos. 10500001–13175000): 30 October 2026

Impact Assessment

The listing adds 31,75,000 shares to the tradable float of Concord Drugs Limited, though most shares (26,75,000) remain under lock-in until October 2026 and a smaller tranche (5,00,000) until October 2027. Immediate free-float impact is minimal given the lock-in constraints. The preferential allotment at Rs. 36.30 signals promoter and investor confidence at that price point. Market impact is limited to existing shareholders and traders in Scrip Code 538965.